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Where does that leave the clinician taking care of this growing
population of patients? Still in limbo, I=m afraid. CLI patients
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This interesting manuscript from the respected St George=s
Vascular Institute evaluated three different models of risk pre-
diction in a single institution=s population of patients with
severe (critical) limb ischemia (CLI) who underwent revascu-
larization, of which, 35% had ischemic rest pain and the remain-
ing 65% had tissue loss. Survival and amputation-free survival
(AFS) were analyzed by applying predictive factors from the
Bypass Versus Angioplasty in Severe Ischemia of the Leg
(BASIL), the national vascular registry in Finland (FINNVASC), and
Edifoligide for the Prevention of Infrainguinal Vein Graft Failure
(PREVENT) III models. A concise table created by the authors
nicely compares the relevant factors in eachmodel for those readers
who may not be familiar with them. Receiver operator character-
istic (ROC) curve analysis was used to evaluate relative predictive
power.
The premise of this study no doubt stems from the observa-
tion in the BASIL trial that patients who survived 2 years fared
better with bypass than with endovascular therapy.1 Thus, identi-
fying CLI patients before intervention who are unlikely to survive
long enough to benefit from aggressive revascularization or un-
likely to salvage their limbs, even with such intervention, would be
clinically useful.
The authors= analysis concluded that all three models were
modest predictors of short-term and intermediate-term survival
and of short term AFS, with area-under-the-ROC-curve values
ranging from 0.54-0.72, depending on the end point and
follow-up time. As the authors acknowledge, area-under-the-ROC
values 0.7 should be used with caution, and although perhaps
clinically useful, the models in their “current form cannot be used
exclusively at the expense of clinical” judgment.omprise a heterogeneous population with respect to risk of am-
utation and death. The termCLI is poorly defined, as is its natural
istory. Consider that the CLI patients who met accepted hemo-
ynamic definitions and were treated with placebo in the Circulase
Mitsubishi Pharma Corp, Tokyo, Japan) trial exhibited an 87%
imb salvage rate at 6 months,2 similar to the outcomes of patients
reated with endovascular therapy and bypass in the BASIL trial.1
n addition, because of the global epidemic of diabetes, most
ascular specialists are treating an ever-increasing number of dia-
etic individuals with “CLI.” As an aside, it is noteworthy that it
as never intended to apply this term to patients with diabetes
ecause of the confounding factors of neuropathy, ischemia, and
nfection, along with the recognition that people with diabetes
equire higher levels of perfusion for wounds to heal than those
ithout diabetes.3
It seems clear that we will never be able select the most
ppropriate therapy and analyze the outcomes of such therapies for
CLI” until we have better definitions of the input and the output.
ecause CLI constitutes a diverse disease spectrum, a better defi-
ition of the input would require a new classification system that
ncludes gradations of ischemia, wound extent, location, and
epth, as well as infection. With respect to the output, what
utcomes are most clinically important? Patient survival is certainly
ne measure. But what about other outcome measures such as
ajor adverse cardiovascular events, AFS, limb reintervention rate,
elief of pain, wound healing, quality of life, ability to ambulate and
ive independently, and functional status?4,5
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